Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin-III Denver, a reactive site variant.

A W Stephens, B S Thalley, C H Hirs

    The Journal of Biological Chemistry
    |January 25, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [<sup>18</sup>F]PI-2620 PET/MRI study.

    European journal of nuclear medicine and molecular imaging·2022
    Same author

    [1] Automated sample injection in amino acid analyzers.

    Methods in enzymology·2012
    Same author

    Preface.

    Methods in enzymology·2012
    Same author

    A gamma-ray burst at a redshift of z approximately 8.2.

    Nature·2009
    Same author

    Medium-chain acyl-coenzyme A dehydrogenase bound to a product analogue, hexadienoyl-coenzyme A: effects on reduction potential, pK(a), and polarization.

    Biochemistry·2000
    Same author

    Escort aptamers: a delivery service for diagnosis and therapy.

    The Journal of clinical investigation·2000

    Antithrombin-III Denver is a mutant protein with a Ser394Leu substitution, significantly impairing thrombin binding. This genetic defect reduces the protein

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Genetics

    Background:

    • Antithrombin-III is a crucial inhibitor of serine proteases.
    • Mutations in Antithrombin-III can lead to bleeding disorders.
    • Antithrombin-III Denver is a known variant with impaired function.

    Purpose of the Study:

    • To characterize the molecular defect in Antithrombin-III Denver.
    • To identify the specific mutation responsible for altered protein function.
    • To quantify the impact of the mutation on thrombin binding kinetics.

    Main Methods:

    • Affinity separation using heparin-Sepharose.
    • Gel filtration chromatography.
    • Tryptic peptide mapping and Vydac C18 fractionation.
    • Protein sequencing and synthesis.

    Related Experiment Videos

  • Kinetic analysis of thrombin binding.

    • Main Results:

    • A unique tryptic peptide from Antithrombin-III Denver was identified, corresponding to residues 394-399.
    • The mutation was identified as a Ser394Leu substitution at the reactive site.
    • Thrombin binding to Antithrombin-III Denver showed a drastic reduction in the second-order rate constant (approx. 4000-fold reduction in the presence of heparin).

    Conclusions:

    • The Ser394Leu substitution is the primary defect in Antithrombin-III Denver.
    • This mutation significantly impairs the ability of antithrombin to inhibit thrombin.
    • The findings highlight the importance of the reactive site serine in antithrombin function.